

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the Shares. Potential investors should read the prospectus dated 8 April 2011 (the "Prospectus") issued by China NT Pharma Group Company Limited (the "Company") for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless defined herein, terms in this announcement shall have the same meanings as those defined in the Prospectus.



China NT Pharma Group Company Limited **中國泰凌醫藥集團有限公司**

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

- Number of Offer Shares in the Global Offering :** 357,032,000 Shares comprising 270,479,000 New Shares to be offered by the Company and 86,553,000 Sale Shares to be offered by the Selling Shareholders (subject to the Over-allotment Option)
- Number of Hong Kong Offer Shares :** 35,703,500 New Shares (subject to reallocation)
- Number of International Placing Shares :** 321,328,500 Shares comprising 234,775,500 New Shares to be offered by the Company and 86,553,000 Sale Shares to be offered by the Selling Shareholders (subject to reallocation and the Over-allotment Option)
- Maximum Offer Price :** HK\$6.00 per Share, plus 1% brokerage, SFC transaction levy of 0.003%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
- Nominal value :** US\$0.00000008 per Share
- Stock Code :** 1011

Sole Global Coordinator and Sole Sponsor



Joint Bookrunners and Joint Lead Managers



**Goldman
Sachs**

Application has been made by the Company to the Listing Committee of the Stock Exchange for the granting of the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to Global Offering comprising 270,479,000 New Shares to be offered by the Company and 86,553,000 Sale Shares to be offered by the Selling Shareholders (subject to the Over-allotment Option) and any additional Shares representing up to 4.1% of the issued share capital of the Company as at the Listing Date which may fall to be issued pursuant to the exercise of the options which may be granted under the Pre-IPO Share Option Scheme as described in Appendix VIII to the Prospectus. In the event the Over-allotment Option is exercised, an announcement will be made by the Company.

Applications of the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus.

Applicants who wish to be allotted the Hong Kong Offer Shares in their own names should (i) complete and sign the **WHITE** Application Forms or (ii) submit applications online through the designated website of the **HK eIPO White Form** Service Provider at **www.hkeipo.hk** under the **HK eIPO White Form** service. Applicants who wish to have the Hong Kong Offer Shares allotted in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant's stock accounts or the stock accounts of their designated CCASS Participants should (i) complete and sign the **YELLOW** Application Forms; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Friday, 8 April 2011 until 12:00 noon on Wednesday, 13 April 2011, from the following locations:

1. UBS AG, Hong Kong Branch, 52nd Floor, Two International Finance Centre, 8 Finance Street, Central, Hong Kong
2. Goldman Sachs (Asia) L.L.C., 68th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong
3. ABCI Capital Limited, 13th Floor, Fairmont House, 8 Cotton Tree Drive, Central, Hong Kong

4. Any of the following branches of **Bank of China (Hong Kong) Limited:**

	Branch name	Branch address
Hong Kong Island:	Bank of China Tower Branch	3/F, 1 Garden Road
	Chai Wan Branch	Block B, Walton Estate, 341-343 Chai Wan Road, Chai Wan
Kowloon:	Mong Kok (President Commercial Centre) Branch	608 Nathan Road, Mong Kok
	Hung Hom (Eldex Industrial Building) Branch	21 Ma Tau Wai Road, Hung Hom
New Territories:	Tuen Mun Town Plaza Branch	Shop 2, Tuen Mun Town Plaza Phase II
	East Point City Branch	Shop 101, East Point City, Tseung Kwan O

Any of the following branches of **The Bank of East Asia, Limited:**

	Branch name	Branch address
Hong Kong Island:	Main Branch	10 Des Voeux Road Central
	399 Hennessy Road Branch	G/F, Eastern Commercial Centre, 399 Hennessy Road, Wanchai
Kowloon:	Mongkok North Branch	G/F, Kalok Building, 720-722 Nathan Road, Mongkok
	Hoi Yuen Road Branch	Unit 1, G/F, Hewlett Centre, 54 Hoi Yuen Road
New Territories:	Shatin Plaza Branch	Shop 3-4, Level 1, Shatin Plaza

Any of the following branches of **Wing Lung Bank Limited:**

	Branch name	Branch address
Hong Kong Island:	Head Office	45 Des Voeux Road Central
	North Point Branch	361 King's Road
Kowloon:	Tsim Sha Tsui Branch	4 Carnarvon Road
New Territories:	Tsuen Wan Branch	251 Sha Tsui Road
	Sheung Shui Branch	128 San Fung Avenue

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Friday, 8 April 2011 until 12:00 noon on Wednesday, 13 April 2011 at the Depository Counter of HKSCC at 2nd Floor, Infinitus Plaza, 199 Des Voeux Road Central, Hong Kong.

Applicants applying by **HK eIPO White Form** may submit applications to the **HK eIPO White Form** Service Provider through the designated website **www.hkeipo.hk** from 9:00 a.m. on Friday, 8 April 2011 until 11:30 a.m. on Wednesday, 13 April 2011 (or such later time as described under the section headed “How to Apply for Hong Kong Offer Shares — Effect of bad weather on the opening of the application lists” in the Prospectus) (24 hours daily, except on the last application day).

CCASS Participants can input **electronic application instructions** from 9:00 a.m. on Friday, 8 April 2011 until 12:00 noon on Wednesday, 13 April 2011.

Please refer to the “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” sections of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offer.

The Company expects to announce the final Offer Price, the level of indications of interest in the International Placing, results of applications and basis of allocation of the Hong Kong Offer Shares under the Hong Kong Public Offer on Tuesday, 19 April 2011, in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese), and on the Company’s website at **www.ntpharma.com** and the website of the Stock Exchange at **www.hkexnews.hk**. Results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offer will be available through a variety of channels from Tuesday, 19 April 2011.

Dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, 20 April 2011. The Shares will be traded in board lots of 500 Shares each. The Company will not issue any temporary document of title.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 8 April 2011

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Mr. Ng Yuk Keung; the non-executive Directors are Ms. Chin Yu, Dr. Qian Wei and Mr. Stephen Cheuk Kin Law; and the independent non-executive Directors are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.

Please also refer to the published version of this announcement in the South China Morning Post.